醫療保健市場研究

---

Engaging in thorough healthcare 市場研究 helps companies understand market dynamics, regulatory changes, and consumer preferences, ensuring they can make strategic decisions that drive growth and innovation.

您想確保您的醫療保健服務在競爭日益激烈的市場中取得成功嗎？全面的醫療保健市場研究可以提供您所需的策略見解。透過利用醫療保健市場研究，企業可以了解推動市場趨勢的關鍵因素，識別潛在挑戰，並制定策略以最大限度地提高其市場佔有率和獲利能力。

Healthcare Market Research: How Leading Firms Convert Evidence Into Market Access

Healthcare market research now decides which therapies launch at premium prices, which devices win formulary placement, and which staffing brands attract scarce clinical talent. The discipline has matured from descriptive surveys into a precision instrument tied directly to commercial outcomes.

The firms pulling ahead treat research as launch infrastructure, not a checkbox before approval. They sequence evidence across HTA submission requirements, payer value stories, and KOL networks before the first sales rep is hired. The payoff shows up in faster reimbursement, tighter indication prioritization, and a defensible payer value story when negotiations begin.

Why Healthcare Market Research Now Drives Commercial Strategy

Three forces have elevated the function. Payers demand real-world evidence beyond pivotal trial data. Regulators in the EU, UK, and Canada coordinate joint HTA submissions, raising the evidentiary bar. Patient advocacy groups now influence formulary decisions in oncology, rare disease, and immunology.

The implication is structural. A Fortune 500 manufacturer entering gastric oncology in the United States cannot rely on KOL opinion alone. The payer value story must integrate patient-reported outcomes, physician treatment sequencing logic, and competitive benchmarking against established regimens. Each input requires a different research instrument and a different respondent pool.

SIS International Research has observed that manufacturers who integrate patient interviews with oncologist panels during Phase II, rather than after approval, compress time-to-formulary by quarters because the value dossier arrives at P&T committees with the clinical narrative already validated.

The Four Evidence Streams Behind a Defensible Launch

Sophisticated launch teams build four parallel evidence streams. Each answers a question payers, prescribers, or patients will ask within the first eighteen months of commercialization.

Patient journey mapping. Structured interviews with diagnosed patients reveal where diagnostic delays, referral bottlenecks, and adherence breakdowns occur. In gastric and gastroesophageal junction cancers, the journey from symptom onset to oncology referral often spans multiple primary care visits. That delay shapes how a new therapy must be positioned against standard of care.

KOL mapping and physician panels. Oncologists, specialists, and family physicians weight efficacy, tolerability, and administration burden differently. A KOL map identifies the fifty to one hundred opinion leaders whose published guidance moves community prescribing, then layers in the regional advocates who shape institutional protocols at NCCN-affiliated centers and academic medical systems.

Payer and HTA evidence. Submission-grade evidence requires structured interviews with medical directors, pharmacy benefit managers, and HTA reviewers across NICE, CADTH, IQWiG, and HAS. The payer value story must hold up under cost-effectiveness scrutiny in each market, not just the home geography.

Competitive intelligence. Biosimilar competitive intelligence, pipeline tracking, and indication prioritization analytics determine which therapeutic areas justify capital. Manufacturers who skip this step often launch into segments where a biosimilar entry within twenty-four months erases pricing power.

What Distinguishes Leading Healthcare Market Research Programs

The conventional approach treats each research wave as a discrete deliverable. The better approach treats the program as a single longitudinal evidence base that compounds over the launch sequencing window.

Three practices separate leaders. They recruit hard-to-reach respondents directly rather than relying on syndicated panels. Gastric oncology patients, pediatric rare disease caregivers, and interventional cardiologists rarely sit in standing panels at sufficient density. They run mixed-method designs that pair quantitative sizing with qualitative depth. A two-hundred-respondent quantitative survey of Brazilian healthcare professionals tells you market structure. Forty in-depth interviews tell you why prescribing patterns deviate from guidelines. They calibrate evidence across geographies before consolidating into a global value story, recognizing that French HAS reviewers, German G-BA committees, and US commercial payers weight evidence differently.

Across SIS International’s healthcare engagements spanning the US, UK, France, Canada, Japan, Brazil, and China, the consistent pattern is that programs designed around the payer’s evidentiary question, rather than the manufacturer’s marketing question, achieve formulary positioning at parity or premium pricing. The reframing is small. The commercial impact is not.

The SIS Healthcare Evidence Stack

A useful way to organize a launch research program is by decision horizon and respondent type. The matrix below frames the choice.

Source: SIS International Research

The stack is not theoretical. SIS has executed each layer across oncology, CME market sizing for family physicians, healthcare staffing persona development in the UK, France, and Canada, and rare disease patient recruitment in China. The recurring lesson is that single-layer programs underperform integrated stacks by wide margins on launch readiness scoring.

Geographic Calibration: Where the Evidence Must Differ

Global launches fail when manufacturers extrapolate US payer logic into European HTA submissions or Asian regulatory pathways. The evidence requirements diverge meaningfully.

NICE in the UK weights incremental cost-effectiveness ratios against a defined willingness-to-pay threshold. IQWiG in Germany applies a comparative benefit assessment that often demands head-to-head data. PMDA in Japan expects local patient data even when global trials suffice elsewhere. ANVISA approvals in Brazil require evidence calibrated to the public SUS system and private payer mix. Treating these as a single market access exercise produces submissions that satisfy none of them.

Healthcare staffing follows the same logic. Persona development for clinical workers in the UK NHS context requires different segmentation variables than France’s regional ARS structure or Canada’s provincial health authorities. B2B and B2C personas must reflect how each system actually procures and retains clinical labor.

The Conversion From Evidence To Commercial Outcome

The final test of any healthcare market research program is whether it changes a launch decision. Programs that produce binders nobody reads have failed regardless of methodological rigor. Programs that reshape indication prioritization, accelerate KOL engagement sequencing, or force a pricing recalibration have earned their budget.

VP-level decision makers at Fortune 500 manufacturers should expect three deliverables from a serious program. A payer value story validated against named HTA precedents. A KOL map with engagement priorities ranked by influence on community prescribing. An indication prioritization model that ranks therapeutic areas by addressable population, competitive intensity, and reimbursement probability. Anything less is descriptive research, not commercial intelligence.

The manufacturers winning in oncology, rare disease, and specialty care treat healthcare market research as the evidentiary spine of commercialization. The discipline has earned that role.

關於 SIS 國際

SIS國際 提供定量、定性和策略研究。我們為決策提供數據、工具、策略、報告和見解。我們也進行訪談、調查、焦點小組和其他市場研究方法和途徑。 聯絡我們 為您的下一個市場研究項目。